This is a routine patent portfolio update with no new financial data or clinical catalysts. Given the company's $1M market cap and history of extreme volatility, traders should not trade on this news alone. Monitor for actual clinical trial results or financing events as the next potential catalysts.
Price Chart
Executive Summary
Clearmind Medicine announced the filing of a European patent application for novel psychedelic compounds targeting PTSD, part of its exclusive worldwide licensing agreement with Yissum. The press release references supportive policy momentum from a recent U.S. Executive Order on psychedelic therapies. This is a routine IP portfolio update with no financial data or clinical milestones, and the company has a market cap of only $1M with a history of extreme volatility.
Key Facts
- Filed European patent application for novel psychedelic compounds targeting PTSD and other mental health disorders.
- Patent application is part of exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
- Company holds exclusive global rights to develop, manufacture, and commercialize novel compounds developed at Yissum.
- Press release cites a market report valuing the global PTSD treatment market at approximately USD 18.5 billion in 2025, projected to reach USD 30.2 billion by 2035.
- Press release references a U.S. Executive Order signed April 18, 2026, directing federal agencies to accelerate research and regulatory review of psychedelic-based therapies.
- Company's intellectual portfolio consists of nineteen patent families, including 31 granted patents.
- No financial data, clinical trial results, or revenue figures were disclosed in the filing.
Financial Impact
No financial figures disclosed. The filing is a routine IP update with no quantifiable financial impact.
Risk Factors
- Patent applications may not be granted or may be granted in a narrower form than sought.
- Company has a very small market cap ($1M) and limited financial resources, increasing dilution risk.
- No clinical data or revenue disclosed; the company remains a pre-revenue clinical-stage biotech.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-051923 |
| Document: ea0289191-6k_clearmind.htm | 0001213900-26-051923 |
| Document: 0001213900-26-051923-index-headers.html | 0001213900-26-051923 |
| Document: 0001213900-26-051923-index.html | 0001213900-26-051923 |
| Document: 0001213900-26-051923.txt | 0001213900-26-051923 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.75%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.26%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.12%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.41%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.27%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers